Prestige Biologics Co Ltd
KOSDAQ:334970
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Prestige Biologics Co Ltd
Operating Income
Prestige Biologics Co Ltd
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
Prestige Biologics Co Ltd
KOSDAQ:334970
|
Operating Income
-₩34.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Operating Income
₩1.2T
|
CAGR 3-Years
22%
|
CAGR 5-Years
10%
|
CAGR 10-Years
17%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Operating Income
-₩123.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Operating Income
-₩36.3B
|
CAGR 3-Years
-50%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Operating Income
₩106.9B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
300%
|
CAGR 10-Years
97%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Operating Income
-₩40.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
Prestige Biologics Co Ltd
Glance View
Prestige Biologics Co., Ltd. engages in research, development, and supplying of pharmaceutical products. The company is headquartered in Cheongju, Chungcheongbuk-Do and currently employs 199 full-time employees. The company went IPO on 2021-03-11. The firm mainly engages in the contract manufacturing service business that produces and supplies biopharmaceuticals; and contract development service business that provides development services including cell culture process and purification process.
See Also
What is Prestige Biologics Co Ltd's Operating Income?
Operating Income
-34.8B
KRW
Based on the financial report for Dec 31, 2025, Prestige Biologics Co Ltd's Operating Income amounts to -34.8B KRW.
What is Prestige Biologics Co Ltd's Operating Income growth rate?
Operating Income CAGR 5Y
-9%
Over the last year, the Operating Income growth was 4%. The average annual Operating Income growth rates for Prestige Biologics Co Ltd have been 2% over the past three years , -9% over the past five years .
